Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | ANO1 | Q5XXA6 | 3/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.38 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29727678 | 0.87 | CNR2 (0.45) | CNR1ANO1POLB | |
| SCHEMBL18285292 | 0.87 | CYP1A2 (0.36) | CNR1POLBIKBKBCHUKSCN10A | |
| SCHEMBL18285345 | 0.87 | L3MBTL1 (0.47) | CNR1ANO1SCN10ASUCNR1 | |
| SCHEMBL29727644 | 0.87 | L3MBTL1 (0.47) | CNR1ANO1SCN10ASUCNR1 | |
| SCHEMBL18285279 | 0.87 | CNR2 (0.45) | CNR1ANO1POLB | |
| SCHEMBL18285281 | 0.86 | JAK2 (0.40) | TP53LMNAANO1JAK2POLB | |
| SCHEMBL29727624 | 0.85 | MEN1 (0.39) | CNR1ANO1POLBIKBKBCHUK | |
| SCHEMBL18512930 | 0.85 | SHMT1 (0.36) | CNR1LMNAANO1POLBIKBKB | |
| SCHEMBL19641940 | 0.85 | MEN1 (0.39) | CNR1ANO1POLBIKBKBCHUK | |
| SCHEMBL18285322 | 0.84 | SLC6A3 (0.36) | CNR1HSD11B1ANO1POLBIKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109563049-B | Imidazole compounds as EAAT3 inhibitors | 豪夫迈·罗氏有限公司 | 2022-11-29 | — | — | CN | disclosed |
| CN-109071451-B | Pyrazole compounds as EAAT3 inhibitors | 豪夫迈·罗氏有限公司 | 2022-07-15 | — | — | CN | disclosed |
| CN-107531642-B | Imidazole derivatives | 豪夫迈·罗氏有限公司 | 2021-06-22 | — | — | CN | disclosed |
| EP-3526201-B1 | IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-11-18 | — | — | EP | disclosed |
| EP-3526201-B1 | IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-11-18 | — | — | EP | disclosed |
| CN-107922391-B | Pyridine and pyrimidine derivatives | 豪夫迈·罗氏有限公司 | 2020-09-25 | — | — | CN | disclosed |
| EP-3464246-B1 | PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-07-08 | — | — | EP | disclosed |
| EP-3464246-B1 | PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-07-08 | — | — | EP | disclosed |
| US-10556870-B2 | Imidazole compounds as EAAT3 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-10556870-B2 | Imidazole compounds as EAAT3 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-20180162824-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180162824-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180118692-A1 | IMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-05-03 | — | — | US | disclosed |
| WO-2018069362-A1 | IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-04-19 | — | — | WO | disclosed |
| EP-3303299-A1 | IMIDAZOLE DERIVATIVES | H. Hoffnabb-La Roche Ag (CH) | 2018-04-11 | — | — | EP | disclosed |
| WO-2017202896-A1 | PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017202896-A1 | PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017025523-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-02-16 | — | — | WO | disclosed |
| WO-2017025523-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-02-16 | — | — | WO | disclosed |
| WO-2016193235-A1 | IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162824-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES | MC3R, MC2R, NPY1R | CNR1 14/4885TP53 3642/4885MDM2 4721/4885 |
| US-20180118692-A1 | IMIDAZOLE DERIVATIVES | DRD3, GABRR3, DRD4 | CNR1 214/4885TP53 3961/4885MDM2 4433/4885 |
| US-10556870-B2 | Imidazole compounds as EAAT3 inhibitors | SLC1A1, SLC1A3, SLC1A2 | CNR1 2639/4885TP53 3665/4885MDM2 4258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.